Scientific Overview: 1st-line brigatinib approved for ALK+ NSCLC 2020. Brigatinib 1st-line — ALTA-1L superior to crizotinib
Mechanism of Action: 2nd-Gen ALK + EGFR TKI (1st-line)
Purity: ≥99% | Molecular Formula: N/A
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Price does not set this product.
Stock availability does not exist this product.
Scientific Overview: 1st-line brigatinib approved for ALK+ NSCLC 2020. Brigatinib 1st-line — ALTA-1L superior to crizotinib
Mechanism of Action: 2nd-Gen ALK + EGFR TKI (1st-line)
Purity: ≥99% | Molecular Formula: N/A
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
| Effect | 2nd-Gen ALK + EGFR TKI (1st-line) |
|---|---|
| Purity | ≥99% |
| Molecular Formula | |
| CAS Number |
